Pharmacol Res Perspect. 2016 Feb 23;4(2):e00221. doi: 10.1002/prp2.221. eCollection 2016 Apr.

Comparative effects of immediate-release and extended-release aspirin on basal and bradykinin-stimulated excretion of thromboxane and prostacyclin metabolites.

Pharmacology research & perspectives

Jorge L Gamboa, Jessica K Devin, Claudia E Ramirez, Chang Yu, Hui Nian, Rhonda H Lee, Nancy J Brown

PMID: 27069632 PMCID: PMC4804312 DOI: 10.1002/prp2.221

Abstract

A goal of aspirin therapy is to inhibit thromboxane production and platelet aggregation without inhibiting endothelial production of the vasodilator and anti-thrombotic prostacyclin. This study tested the hypothesis that extended-release aspirin (NHP-554C) would have increased selectivity for inhibition of basal and simulated thromboxane formation compared to immediate-release aspirin (ASA). Thirty-six healthy subjects were randomized to NHP-554C or ASA groups. Within each group, subjects were randomized to 5-day treatment with 81 mg/d, 162.5 mg/d and placebo in a crossover design in which treatment periods were separated by 2-week washout. On the fifth day of treatment, 81 mg/d and 162.5 mg/d ASA reduced basal urinary excretion of the stable thromboxane metabolite 11-dehydro-thromboxane B2 62.3% and 66.2% and basal excretion of the stable prostacyclin metabolite 2,3-dinor-6-keto-PGF1α 22.8% and 26.5%, respectively, compared to placebo. NHP-554C 81 mg/d and 162.5 mg/d reduced 11-dehydro-thromboxane B2 53% (P = 0.03 vs. ASA 81 mg/d) and 67.9% and 2,3-dinor-6-keto-PGF1α 13.4% and 18.5%, respectively. NHP-554C 81 mg/d did not significantly reduce basal excretion of the prostacyclin metabolite. Both doses of ASA and NHP significantly reduced excretion of both thromboxane and prostacyclin metabolites following intravenous bradykinin. During NHP-554C 162.5 mg/d, but not during ASA, bradykinin significantly increased urinary 2,3-dinor-6-keto-PGF1α. Nevertheless, 11-dehydro-thromboxane B2 and 2,3-dinor-6-keto-PGF1α responses to bradykinin were statistically similar during ASA and NHP-554C. In conclusion, at doses of 81 and 162.5 mg/d immediate- and extended-release aspirin selectively decrease basal thromboxane production. Both forms of aspirin decrease bradykinin-stimulated thromboxane and prostacyclin production, but some stimulated prostacyclin production remains during treatment with NHP-554C.

Keywords: Aspirin; bradykinin; prostacyclin; thromboxane

References

1. J Biol Chem. 1976 Sep 25;251(18):5814-6 - PubMed
2. N Engl J Med. 1997 Apr 3;336(14):973-9 - PubMed
3. Adv Prostaglandin Thromboxane Leukot Res. 1983;11:265-6 - PubMed
4. Circ Res. 1981 Nov;49(5):1152-63 - PubMed
5. J Chromatogr. 1993 Feb 26;612(2):179-85 - PubMed
6. N Engl J Med. 1989 Dec 28;321(26):1825-8 - PubMed
7. Postgrad Med. 2015 Aug;127(6):573-80 - PubMed
8. N Engl J Med. 1983 Aug 18;309(7):396-403 - PubMed
9. Lancet. 2009 May 30;373(9678):1849-60 - PubMed
10. FASEB J. 1991 Jun;5(9):2304-12 - PubMed
11. Br J Pharmacol. 1999 Sep;128(1):241-7 - PubMed
12. Br J Pharmacol. 1984 Jul;82(3):565-75 - PubMed
13. Coron Artery Dis. 1994 Jul;5(7):617-23 - PubMed
14. J Clin Invest. 1983 Nov;72(5):1658-71 - PubMed
15. J Chromatogr B Biomed Appl. 1994 Mar 4;653(2):117-22 - PubMed
16. Nature. 1976 Oct 21;263(5579):663-5 - PubMed
17. N Engl J Med. 1991 Oct 17;325(16):1137-41 - PubMed
18. Ann Intern Med. 1994 Feb 1;120(3):184-9 - PubMed
19. Br J Clin Pharmacol. 1989 Nov;28(5):573-9 - PubMed
20. Pharmacol Res Perspect. 2016 Feb 23;4(2):e00221 - PubMed
21. Br J Pharmacol. 2000 Sep;131(1):145-51 - PubMed
22. Circulation. 1991 Aug;84(2):679-85 - PubMed
23. Proc Natl Acad Sci U S A. 1975 Aug;72(8):2994-8 - PubMed

Publication Types

• Journal Article

Grant support

• K23 DK100533/DK/NIDDK NIH HHS/United States
• K23 HL119602/HL/NHLBI NIH HHS/United States
• U54 TR000123/TR/NCATS NIH HHS/United States